Insulins for the long term management of diabetes mellitus in dogs: a review.

Canine Med Genet. February 2022;9(1):1.

Robert E Shiel¹, Carmel T Mooney²

¹ School of Veterinary Medicine, University College Dublin, Belfield, Dublin 4, Ireland. robert.shiel@ucd.ie.; ² School of Veterinary Medicine, University College Dublin, Belfield, Dublin 4, Ireland.

Abstract

The year 2021 marked the centenary of the isolation of a therapeutic form of insulin and its successful use in dogs. This was a landmark moment that subsequently and rapidly led to the commercial manufacture of insulin for use in humans. The impact of insulin was almost miraculous as those destined to die from their diabetes mellitus returned to life. Over the past 100 years, insulin formulations have been modified to attempt to provide a predictable and prolonged duration of action while avoiding the development of hypoglycaemia. This has led to an ever-growing variety of insulin types in human medicine, many of which have subsequently been used in dogs. The purpose of this review article is to provide an overview of available insulin types and their application to the chronic management of canine diabetes mellitus.

Keywords

Diabetes mellitus; Dogs; Insulin; Pharmacology;

Article Tools:

Medline

Email to me

Comments:

Erratum In Canine Med Genet. 2022 Mar 4;9(1):3. doi: 10.1186/s40575-022-00115-8

Archives Highlights:

Development of a dog owner caregiving style scale (Lincoln Owner Caregiving Questionnaire, LOCQ) and its relationship with behaviour problems in dogs
Compared to owners of dogs without behaviour problems, owners with high scores for the Disorganised caregiving style predicted dogs with separation related problems or with more than one behaviour problem, owners with high Avoidant caregiving style scores predicted dogs with Fear, and owners with high scores for both Disorganised and Avoidant caregiving styles predicted dogs with Aggressivity problems.

The relationship between radiographic disc calcification score and FGF4L2 genotype in dachshunds.
Most dachshunds with 1 FGF4L2 copy have radiographic disc calcification scores that are associated with substantially lower risk of symptomatic disc disease. Radiographic disc calcification scores are similar in dachshunds with 0 and 1 FGF4L2 copies. Given the high allele frequency of FGF4L2, breeding to produce progeny with 1 FGF4L2 copy is expected to be a more achievable short-term goal for dachshund spinal health breeding programs than breeding for 0 copies. It is recommended that both K-n and FGF4L2 genotype status be considered when choosing dachshund breeding stock.

Factors Associated with Medication Noncompliance in Dogs in New Zealand.
Medication noncompliance was recorded for 47% (71/151) of owners. Increasing dog age was associated with better owner compliance. Forty-seven percent (71/151) of owners reported that "nobody" showed them how to administer the medication. One-third of dog owners (47/151) reported challenges in medicating their pets. The most common reason cited by clients reporting challenges was a resistant pet.

Effective treatment with afoxolaner (NexGard) of Trixacarus caviae in a pet guinea pig.
The animal was treated with a single oral dose of 2.50 mg/kg afoxolaner, and the lesions, presence/absence of mites, and intensity of pruritus were evaluated periodically until 2 months post-treatment. A week after the medication, the lesions were milder, but pruritus was still present and was attributed to the healing process. Further examinations showed significant improvement with the complete remission of clinical signs and no mites at the microscopic examination after 4 weeks.

Duration of efficacy and effect of implant location in adult queens treated with a 9.4 mg deslorelin subcutaneous implant.
The average duration of action of the 9.4 mg deslorelin implant was 790 ± 155 days (range 525-1140 days) with no significant difference in duration or efficacy depending on implantation sites. The 9.4 mg deslorelin implant causes pharmacological sterilization for about 2 years in female cats, is fully reversible, and caused no clinically relevant side effects when administered at both interscapular and periumbilical sites.